Race, Natriuretic Peptides and Physiological Perturbations

University of Alabama at Birmingham80 enrolled

Overview

The purpose of the study is to understand the origins of differential response to beta-blockers in African-Americans and may provide insight regarding racial differences in cardiovascular risk.

The heart is an endocrine organ. The natriuretic peptides are hormones produced in the heart and are secreted in response to increased wall stress in atria and ventricles. The principal circulating NPs are Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP). The endocrine actions of NPs are natriuresis and dilatation of peripheral arteries. The NPs concentrations are elevated in heart failure (HF) and hypertension (HTN) due to volume and pressure overload. Therefore, NPs are used as diagnostic and prognostic markers in heart failure. However, NPs role in healthy individuals is not known. Previous studies have shown that reduced NP levels are associated with a greater risk of HTN. Moreover, African-Americans have lower resting NP levels than Caucasians. We hypothesize that relative NP deficiency in African American compared to Caucasian has the potential to contribute to increase risk of all-cause mortality, HTN, HF and its sequelae. Evidence from multiple clinical trials has positioned beta-blockers as a standard heart failure therapy. Beta-blocker therapy leads to increased NP levels and suppression of Renin-aldosterone-angiotensin system (RAAS) system. Suppression of renin levels by beta-blockers has been shown as a potential mechanism of benefit in HF. However, study shows that beta-blockers are less effective in African-Americans compared to Caucasians in HF treatment. So, the investigators have proposed a pilot study to look for race-based differences in the NP and RAAS response to metoprolol in healthy individuals. Additionally, exercise has been reported to increase NP levels. ANP increases more than BNP with exercise. But there is no data of NP changes in African-American with exercise. So the investigators have proposed a sub-study of race-based difference in ANP and BNP response to exercise. 40 African-American and 40 Caucasians normotensive or pre-hypertensive (healthy) individuals will be enrolled.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Healthy Pre Hypertension

Interventions

Exercise capacity VO2 max determinationOTHER

Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.

Standardized mealsDIETARY_SUPPLEMENT

Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).

Exercise challengeOTHER

Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 40 years * Blood pressure less than 140/90 mm Hg * Able to perform exercise capacity test * BMI 18-30 kg/m2 * Willing to adhere to study drug Exclusion Criteria: * History of cardiovascular disease or use of medications for CVD * History of hypertension or use of BP lowering medications * Blood pressure less than 100/60 mm Hg * Heart rate less than 60 beats/min * Depression * Diabetes or use of anti-diabetic medications * Renal disease (eGFR \< 60ml/min/1.73m2) * Current or prior smokers * Pregnant or use of Hormone Replacement Therapy (HRT) or oral contraceptives (OCP) or steroids

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Outcomes

Primary Outcomes

Change in Plasma BNP After 6-weeks of Beta-Blocker

Mean percentage change in plasma BNP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants

Time frame: 6 weeks

Change in Plasma NT-proBNP After 6-weeks of Beta-Blocker

Mean percentage change in plasma NT-proBNP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants

Time frame: 6 weeks

Change in Plasma MR-proANP After 6-weeks of Beta-Blocker

Mean percentage change in plasma MR-proANP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants

Time frame: 6 weeks

Secondary Outcomes

Change in Plasma BNP After Standardized Exercise Challenge

Mean percentage change in plasma BNP concentrations in response to exercise

Time frame: Mean percentage change in plasma BNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)

Change in Plasma NT-proBNP After Standardized Exercise Challenge

Mean percentage change in plasma NT-proBNP concentrations in response to exercise

Time frame: Mean percentage change in plasma NT-proBNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)

Change in Plasma MR-proANP After Standardized Exercise Challenge

Mean percentage change in plasma MR-proANP concentrations in response to exercise

Time frame: Mean percentage change in plasma MR-proANP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.